Allogene Therapeutics, Inc. ALLO
0.63 USD -0.04 (-5.88%)
Regular-session close
0.63 +0.01 +1.12%
After hours · Nov 20, 7:37 PM ET
0.6192 Day range 0.67
0.6277 52-week range 3.06
- YTD
- -54.18%
- 1 year
- -49.38%
Benzinga news
benzinga.com Allogene Therapeutics Announces Preliminary Safety, Efficacy And Translational Data From Its Phase 1 RESOLUTION Trial Of ALLO-329 At American College Of Rheumatology Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today…
benzinga.com Allogene Therapeutics Q3 2026 Earnings Call Transcript Allogene Therapeutics (NASDAQ:ALLO) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Allogene Therapeutics Q3 EPS $(0.15), Inline Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 21.05 percent increase over losses of $(0.19) per share from the…
